To Evaluate the Safety, Tolerability and Efficacy of R2R01 Combined With SOC as Compared to SOC Alone in Outpatients With Worsening Heart Failure (WHF)

Heart Failure Clinical Trial

Official title:

A Phase 2, Double-Blind, Placebo-Controlled, Dose Range Finding Study to Assess Safety, Tolerability, Efficacy and Pharmacokinetics of the Relaxin Agonist R2R01 Combined With Standard of Care Versus Standard of Care Alone in Outpatients With Worsening Heart Failure (WHF)

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06264310
• Other study ID #: R2R01-WHF-201
• Status: Not yet recruiting
• Phase: Phase 2
• Start date: March 2024
• Est. completion date: March 2025

Study information

• Verified date: February 2024
• Source: River 2 Renal Corp.
• Contact: Guido Magni, MD, PHD
• Phone: 41 794563810
• Email: magniguido[@]yahoo.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This Study Aims to Evaluate the Safety, Tolerability and Efficacy of R2R01 Combined With SOC as Compared to SOC Alone in Outpatients With Worsening Heart Failure (WHF)

Description:

This is a Phase 2, Double-Blind, Placebo-Controlled, Dose Range Finding Study to Assess Safety, Tolerability, Efficacy and Pharmacokinetics of the Relaxin Agonist R2R01 combined with Standard of Care versus Standard of Care Alone in Outpatients with Worsening Heart Failure (WHF). Each patient will undergo a screening period of up to 21 days, an active treatment period of 7 days, and a follow up period of 23 days after the last dose (30 days after the first dose), i.e., a total of up to 51 days total study duration. This study is a four-parallel-cohort study. All patients will be randomized to one of the following Cohorts: 1. Cohort 1 (N=8): Placebo once daily SC for 7 days. 2. Cohort 2 (N=8): 5.0 mg R2R01 once daily SC for 7 days. 3. Cohort 3 (N=8): 7.5 mg R2R01 once daily SC for 7 days. 4. Cohort 4 (N=8): 10.0 mg R2R01 once daily SC for 7 days. All patients will present with worsening heart failure with congestion requiring SOC. The patient, in the opinion of the investigator, should be able to be treated for their symptoms without being admitted to the hospital. The planned 3-day hospitalization is to adequately manage any potential sign of hypotension and should not be required to treat the patient for the intensification of the diuretic therapy or same day IV loop diuretics. During the treatment period no new treatments for WHF should be initiated. This study will be conducted across approximately 8 centers in the US.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 32
• Est. completion date: March 2025
• Est. primary completion date: January 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Able and willing to give written informed consent, and able to follow instructions and comply with follow-up procedures.

2. History of symptomatic HF (heart failure).

3. Male or female = 18 years of age at screening.

4. Previous hospitalization for HF within the last 12 months prior to screening.

5. Patients on optimal background therapy as per local practice for at least 30 days prior to screening and tolerating this well.

6. Patients must present with at least 2 of the following signs / symptoms of

WHF congestion:

1. Dyspnea

2. Orthopnea

3. Fatigue

4. Jugular venous distension

5. Rales

6. Edema

7. Patient requires intensification (doubling the dose, adding another diuretic targeting another tubular segment) of oral diuretics, or IV diuresis for WHF as per Investigator at screening and treated as an outpatient patient.

8. Estimated Glomerular Filtration Rate (eGFR) between 20 and 75 mL/ min/1.73 m2 (calculated using the CKD-EPI equation) at screening.

9. NT-pro-BNP levels at screening:

1. = 1000 pg/mL for patients with LVEF = 40%

2. = 700 pg/mL for patients with LVEF > 40%

3. = 1500 pg/mL for patients with current atrial fibrillation, regardless of LVEF. For patients with BMI = 30 kg/m2 the NT-pro-BNP values are lowered by 20%. The

values are as follows:

1. = 800 pg/mL for patients with LVEF = 40%

2. = 560 pg/mL for patients with LVEF > 40%

3. = 1200 pg/mL for patients with current atrial fibrillation, regardless of LVEF. The most recent LVEF value assessed in the 12 months prior to screening should be used.

10. Systolic Blood Pressure (SBP) = 105 mmHg at screening.

11. Willing and able to stay in the clinic for observation/monitoring for 3 days.

12. Willing to self-administer all SC injections.

Exclusion Criteria:

1. Patients with blood pressure > 180 mmHg or persistent heart rate > 130 bpm at Screening.

2. History of symptomatic hypotension.

3. History of orthostatic hypotension.

4. Temperature > 38.5°C (oral or equivalent) or sepsis or active infection requiring antimicrobial treatment.

5. Clinical evidence of acute coronary syndrome (ACS) currently or within 30 days prior to Screening.

6. Acute Heart Failure (AHF) due to significant arrhythmias, which include any of the following: sustained ventricular tachycardia, bradycardia with sustained ventricular rate < 45 bpm or atrial fibrillation/flutter with sustained ventricular response of > 130 bpm.

7. The daily use of IV or oral steroids (including but not limited to the use of IV or oral steroids for respiratory disorders or COPD). Note, inhaled steroids are allowed.

8. IV antimicrobial treatment for sepsis or active infection.

9. Patients with severe renal impairment defined at Screening eGFR < 20 mL/min/1.73m2 (calculated using the CKD-EPI Equation), and/or those receiving current or planned dialysis or ultrafiltration.

10. Patients with hemoglobin < 10 g/dL, or a history of blood transfusion within the 14 days prior to screening, or active life-threatening gastrointestinal bleeding.

11. Known hepatic impairment (as evidenced by total bilirubin > 3 mg/dL, or increased ammonia levels, if performed) or history of cirrhosis with evidence of portal hypertension such as varices.

12. Significant, uncorrected, left ventricular outflow obstruction, such as obstructive hypertrophic cardiomyopathy or severe aortic stenosis (i.e., aortic valve area < 1.0 cm2 or mean gradient > 40 mmHg on echocardiogram), and/or severe mitral stenosis.

13. Severe aortic insufficiency or severe mitral regurgitation for which surgical or percutaneous intervention is indicated.

14. Documented, prior to or at the time of screening, restrictive amyloid myocardiopathy, or acute myocarditis or hypertrophic obstructive, restrictive, or constrictive cardiomyopathy.

15. Any major solid organ transplant recipient or planned/ anticipated organ transplant within 1 year.

16. Major surgery, including implantable devices (e.g., implantable cardioverter defibrillator, cardiac resynchronization therapy), or major neurologic event including cerebrovascular events, within 30 days prior to screening.

17. History of malignancy of any organ system (other than localized basal cell carcinoma of the skin), treated or untreated, within the past year with a current life expectancy less than 1 year due to the malignancy.

18. Pregnant or nursing (lactating) women, where pregnancy was defined as the state of a female after conception and until the termination of gestate, confirmed by a positive human chorionic gonadotropin laboratory test.

19. Use of other investigational drugs within 30 days prior to Screening.

20. History of known hypersensitivity/prior exposure to R2R01 or serelaxin.

21. Any other medical condition(s) that might put the patient at risk or influence study results in the Investigator's opinion, or that the Investigator deems unsuitable for the study including drug or alcohol abuse or psychiatric, behavioral, or cognitive disorders sufficient to interfere with the patient's ability to understand and comply with the protocol instructions or follow-up procedures.

Related Conditions & MeSH terms

• Heart Failure

Intervention

Drug:
• Placebo
Matching placebo SC injection
• R2R01
Pharmaceutical Form: sterile 2R vials containing 10 mg of R2R01 for SC injection.

Locations

Country	Name	City	State
United States	C&R Research Services USA, Inc.	Cape Coral	Florida
United States	Eastern Shore Research Institute	Fairhope	Alabama
United States	Nature Coast Clinical Research	Inverness	Florida
United States	Jacksonville Center for Clinical Research	Jacksonville	Florida
United States	Amavita Research Services, LLC	Miami	Florida

Sponsors (2)

Lead Sponsor	Collaborator
River 2 Renal Corp.	International HealthCare, LLC

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number and rate of patients with one or more TEAEs (treatment emergent AE's) and/or serious TEAEs as assessed by CTCAE v5.0.	To assess the safety and tolerability of various dose levels of R2R01 in WHF patients at Day 7 and Day 30.	Day 7, Day 30
Primary	Number and rate of patients with one or more TEAEs (treatment emergent AE's) and/or serious TEAEs as assessed by CTCAE v5.0.	To select the appropriate dose for Study R2R01-WHF-202	Day 30
Secondary	Change from Baseline on NT-pro-BNP using descriptive and summary statistics by dose level at Day 7 and Day 30.	To evaluate the effect of R2R01 on NT-pro-BNP as a proxy for cardiac congestion at Day 7 and Day 30.	Day 7, Day 30
Secondary	Change from baseline on Cystatin C and creatinine clearance using descriptive and summary statistics by dose level at Day 7 and Day 30.	To evaluate the effect of R2R01 on Cystatin C and creatinine clearance (eGFR using CKD-EPI Equation using both creatinine and cystatin C) at Day 7 and Day 30.	Day 7, Day 30
Secondary	Number of patients requiring dose adjustment of oral diuretics during the 30-day follow-up.	To evaluate the effect of R2R01 on therapy with diuretics at Day 30.	Day 30
Secondary	Number of patients with an event of: WHF-induced SDAC or other outpatient clinic visits requiring additional intensification of the therapy/IV loop diuretics using descriptive and summary statistics for change from baseline by dose level at Day 30.	To evaluate the effect of R2R01 at Day 30 on: WHF-induced Same Day Access Clinic (SDAC)--or other outpatient clinic visits requiring, additional intensification of the therapy/IV loop diuretics.	Day 30
Secondary	Number of cardiovascular hospitalizations among patients using descriptive and summary statistics for change from baseline by dose level at Day 30.	To evaluate the effect of R2R01 at Day 30 on: Cardiovascular (CV) hospitalizations.	Day 30
Secondary	Number of all-cause hospitalizations among patients using descriptive and summary statistics for change from baseline by dose level at Day 30.	To evaluate the effect of R2R01 at Day 30 on: All-cause hospitalizations.	Day 30
Secondary	Number of patients with CV mortality using descriptive and summary statistics for change from baseline by dose level at Day 30.	To evaluate the effect of R2R01 at Day 30 on: CV mortality.	Day 30
Secondary	Number of patients with all-cause mortality using descriptive and summary statistics for change from baseline by dose level at Day 30.	To evaluate the effect of R2R01 at Day 30 on: All-cause mortality.	Day 30